China CROs Step Out Into The World
This article was originally published in PharmAsia News
Executive Summary
Recent activities by China's leading contract research organizations - Wuxi Pharma's acquisition of U.S.-based AppTec laboratory services, joint ventures between Rundo and Japanese Cronova as well as Medicilon and U.S. firm MPI Research - signal that local Chinese corporations are ready to forge closer partnerships with overseas enterprises to boost their technology. In addition, such cooperation will help facilitate the partners entering each other's market. At present, no Chinese CRO has yet met international good laboratory practices standards owing to a lack of specialized talents to set up and manage GLP laboratories. Analysts say that local CROs must meet international technology standards and close the gap with large multinational CROs to enhance their competitiveness in a global market. (Click here for more)